iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC reduced its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 53.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,178 shares of the company's stock after selling 70,186 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.17% of iTeos Therapeutics worth $478,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Bridgeway Capital Management LLC increased its holdings in iTeos Therapeutics by 5.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company's stock valued at $530,000 after buying an additional 3,305 shares during the last quarter. BVF Inc. IL purchased a new stake in iTeos Therapeutics in the 4th quarter valued at approximately $17,856,000. Balyasny Asset Management L.P. purchased a new stake in iTeos Therapeutics in the 4th quarter valued at approximately $218,000. BNP Paribas Financial Markets acquired a new stake in shares of iTeos Therapeutics during the 4th quarter valued at approximately $461,000. Finally, Ameriprise Financial Inc. lifted its position in shares of iTeos Therapeutics by 233.6% during the 4th quarter. Ameriprise Financial Inc. now owns 205,188 shares of the company's stock valued at $1,576,000 after acquiring an additional 143,672 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on ITOS. Wells Fargo & Company reiterated an "overweight" rating and set a $13.00 price target (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Wedbush restated an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Piper Sandler restated an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Finally, Raymond James set a $12.00 price objective on iTeos Therapeutics in a research report on Wednesday, May 14th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $17.86.

Insiders Place Their Bets

In other news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $8,317,363.86. Following the sale, the insider now owns 3,452,797 shares in the company, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the sale, the insider now owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by company insiders.

iTeos Therapeutics Price Performance

ITOS traded up $0.09 during trading on Thursday, hitting $8.31. The company's stock had a trading volume of 495,625 shares, compared to its average volume of 561,772. The firm's 50 day moving average price is $6.67 and its 200-day moving average price is $7.41. The stock has a market cap of $318.06 million, a PE ratio of -2.64 and a beta of 1.39. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $18.30.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Equities analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.